Broadening clinical trial eligibility criteria to include cancer patients who also have other health conditions could increase trial enrollment.
by Ashley P. Taylor
A study investigates whether a commonly used clinical trial endpoint, progression-free survival, can be used to predict quality of life.
by Jon Kelvey
Hormone therapy may lengthen life in men with hormone-related breast cancer, but this treatment is prescribed less frequently for men than for women.
by Marilyn Fenichel
Forward Look
Cell and molecular biologist Ashani Weeraratna discusses how older patients respond to immunotherapy.
by Sue Rochman
A study suggests high-risk patients do not need chemotherapy.
by Stephen Ornes
Lung cancer deaths are set to surpass breast cancer deaths in many regions.
by Cameron Walker
Drugs approved through this pathway may have limited evidence.
by Lindsey Konkel
New tools are being integrated into the research process to ease patients’ access to clinical trials and improve their experience.
by Bradley Jones
Off-the-shelf equivalents to CAR-T cell therapy are emerging.
From the Editor-In-Chief
The U.S. health care system must adapt to the needs of cancer survivors.
by William G. Nelson, MD, PhD
A study investigates how people who have been diagnosed with cancer feel about being called survivors.
by Jen Tota McGivney
A new vaccine is safe for cancer patients but hard to find.
by Nancy Averett
In the past few decades, most of the progress that has been made against cervical cancer has been in the areas of prevention and early detection.
The U.S. Food and Drug Administration rounded out 2018 with three oncology approvals.
What are the side effects of immune checkpoint inhibitors and how do they arise?
Bob Riter: The Bridge Builder
donate to the AACR